Stanford University School of Medicine – Sakamoto Lab
(focusing on acute myeloid leukemia (AML) research)

Stanford University School of Medicine – Sakamoto Lab (focusing on acute myeloid leukemia (AML) research)
Challenge

AML is a complex, heterogeneous blood cancer driven by multiple genetic mutations and dysregulated molecular pathways. Traditional reductionist approaches—focusing on single genes or linear pathways—failed to capture the full systems-level dynamics, including feedback loops, crosstalk, and nonlinear interactions that govern leukemia progression, drug resistance, and relapse. The lab needed a comprehensive, integrative model to accelerate mechanistic understanding and identify novel therapeutic targets.

How CytoSolve Helped

The Sakamoto Lab in collaboration with CytoSolve built the world’s first full-scale computational systems architecture of AML. CytoSolve’s platform:

  • Integrated thousands of molecular pathways from peer-reviewed literature into a dynamic, scalable model.
  • Mapped interconnections across oncogenes, tumor suppressors, signaling cascades, and microenvironment interactions.
  • Enabled quantitative simulation of AML subtypes under various genetic and therapeutic perturbations.

Key Benefits Realized

  • First Comprehensive Systems Model
    Created an unprecedented whole-systems architecture of AML, revealing previously hidden feedback loops and pathway crosstalk critical to leukemogenesis.
  • Novel Mechanistic Insights
    Identified non-obvious drivers of drug resistance and relapse, including convergent downstream mechanisms across genetically diverse AML subtypes.
  • Accelerated Target Discovery
    Prioritized high-impact intervention points with quantitative synergy predictions—shortening the hypothesis-to-validation cycle from years to months.
  • Enhanced Grant & Publication Impact
    Provided rigorous, computable mechanistic evidence that strengthened funding proposals and peer-reviewed publications.

Outcome

The Sakamoto Lab in collaboration with CytoSolve achieved the first full-scale systems-level understanding of AML, transforming fragmented gene-centric views into an integrated, predictive model. This breakthrough has accelerated target identification, informed combination therapy design, and positioned the lab at the forefront of systems oncology—paving the way for more effective, personalized treatments for this aggressive leukemia. This collaboration demonstrates how CytoSolve’s infrastructure uncovers the true molecular systems architecture of complex diseases, enabling paradigm-shifting advances in biomedical research.